CD16+ Monocytes in Coronary Heart Disease (CHD) (PHAMOS)

Martin-Luther-Universität Halle-Wittenberg

Status: Completed

Conditions: Coronary Heart Disease

Study type: Observational

Funder types: Other

Identifiers

NCT01442948

CD16PHAMOS

Details and patient eligibility

About

Monocytes may be separated into phenotypically and functionally distinct cell types by the presence or absence of the lipopolysaccharide receptor CD14 and the Fcγ-receptor CD16. The investigators hypothesize that the total numbers of CD16+ monocytes are significantly related to cardiovascular outcome in patients with angiographically proven coronary heart disease.

Enrollment: 1,000 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• angiographically proven coronary heart disease
• Age > 18 years

Exclusion criteria

• life expectancy < 12 months
• inability to participate in the trial (to give written informed consent)

Trial design

1,000 participants in 2 patient groups

Acute coronary syndrome

Stable Angina